Treating influenza with neuraminidase inhibitors: an update of the literature

References

• Centers for Disease Control and Prevention (CDC). Key facts about influenza (Flu). [cited 2024 Jun 11]. Available from: https://www.cdc.gov/flu/about/keyfacts.htm
   Google Scholar
• WHO. Influenza (seasonal). [cited 2024 Jun 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
   Google Scholar
• WHO. Guidelines for the clinical management of severe illness from influenza virus infections. Geneva; 2022 [cited 2024 Jun 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK579105/
   Google Scholar
• Javanian M, Barary M, Ghebrehewet S, et al. A brief review of influenza virus infection. J Med Virol. 2021 Aug;93(8):4638–4646. doi: 10.1002/jmv.26990
   PubMed Web of Science ®Google Scholar
• Toots M, Plemper RK. Next-generation direct-acting influenza therapeutics. Transl Res. 2020 Jun;220:33–42. doi: 10.1016/j.trsl.2020.01.005
   PubMed Web of Science ®Google Scholar
• Smith BJ, Colman PM, Von Itzstein M, et al. Analysis of inhibitor binding in influenza virus neuraminidase. Protein Sci. 2001 Apr;10(4):689–696. doi: 10.1110/ps.41801
   PubMed Web of Science ®Google Scholar
• Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010 Apr;Suppl 65(Suppl 2):ii5–ii10. doi: 10.1093/jac/dkq015
   Google Scholar
• Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005 Sep 29;353(13):1363–1373. doi: 10.1056/NEJMra050740
   PubMed Web of Science ®Google Scholar
• Cheng VC, To KK, Tse H, et al. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev. 2012 Apr;25(2):223–263. doi: 10.1128/CMR.05012-11
   PubMed Web of Science ®Google Scholar
• Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006 Jan;69(1):39–45. doi: 10.1016/j.antiviral.2005.10.002
   PubMed Web of Science ®Google Scholar
• Chairat K, Tarning J, White NJ, et al. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J Clin Pharmacol. 2013 Feb;53(2):119–139. doi: 10.1177/0091270012440280
   PubMed Web of Science ®Google Scholar
• Principi N, Camilloni B, Alunno A, et al. Drugs for influenza treatment: is there significant news? Front Med. 2019;6:109. doi: 10.3389/fmed.2019.00109
   PubMed Web of Science ®Google Scholar
• Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895–902. doi: 10.1093/cid/ciy874
   PubMedGoogle Scholar
• Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza a H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014 May;2(5):395–404. doi: 10.1016/S2213-2600(14)70041-4
   PubMed Web of Science ®Google Scholar
• Katzen J, Kohn R, Houk JL, et al. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. Clin Infect Dis. 2019 Jun 18;69(1):52–58. doi: 10.1093/cid/ciy860
   PubMed Web of Science ®Google Scholar
• Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017 Nov 1;72(11):2990–3007. doi: 10.1093/jac/dkx271
   PubMed Web of Science ®Google Scholar
• Engelhard D, Mohty B, de la Camara R, et al. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis. 2013 Jun;15(3):219–232. doi: 10.1111/tid.12054
   PubMed Web of Science ®Google Scholar
• Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015 May 2;385(9979):1729–1737. doi: 10.1016/S0140-6736(14)62449-1
   PubMed Web of Science ®Google Scholar
• Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348(apr09 2):g2547. doi: 10.1136/bmj.g2547
   PubMedGoogle Scholar
• Thorlund K, Awad T, Boivin G, et al. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis. 2011 May 19;11(1):134. doi: 10.1186/1471-2334-11-134
   PubMedGoogle Scholar
• Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008 Jan 31;13(5):3–4. doi: 10.2807/ese.13.05.08026-en
   Google Scholar
• Su CP, Chan KA, Huang CT, et al. Inhaled zanamivir vs oral oseltamivir to prevent influenza-related hospitalization or death: a nationwide population-based quasi-experimental study. Clin Infect Dis. [2022 Oct 12];75(8):1273–1279. doi: 10.1093/cid/ciac217
   PubMed Web of Science ®Google Scholar
• Slain D. Intravenous zanamivir: a viable option for critically ill patients with influenza. Ann Pharmacother. 2021 Jun;55(6):760–771. doi: 10.1177/1060028020963616
   PubMed Web of Science ®Google Scholar
• Scott LJ. Peramivir: a review in uncomplicated influenza. Drugs. 2018 Sep;78(13):1363–1370. doi: 10.1007/s40265-018-0981-8
   PubMed Web of Science ®Google Scholar
• Barroso L, Treanor J, Gubareva L, et al. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther. 2005;10(8):901–910. doi: 10.1177/135965350501000805
   PubMed Web of Science ®Google Scholar
• Whitley R, Laughlin A, Carson S, et al. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials. Antivir Ther. 2015;20(7):709–719. doi: 10.3851/IMP2874
   PubMed Web of Science ®Google Scholar
• Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010 Nov;54(11):4568–4574. doi: 10.1128/AAC.00474-10
   PubMed Web of Science ®Google Scholar
• Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011 Nov;55(11):5267–5276. doi: 10.1128/AAC.00360-11
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011 Oct;9(10):851–857. doi: 10.1586/eri.11.112
   PubMed Web of Science ®Google Scholar
• Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antiviral Chem Chemother. 2010;21(2):71–84. doi: 10.3851/IMP1688
   PubMedGoogle Scholar
• Kubo S, Tomozawa T, Kakuta M, et al. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother. 2010 Mar;54(3):1256–1264. doi: 10.1128/AAC.01311-09
   PubMed Web of Science ®Google Scholar
• Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010 Jun;54(6):2575–2582. doi: 10.1128/AAC.01755-09
   PubMed Web of Science ®Google Scholar
• Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010 Nov 15;51(10):1167–1175. doi: 10.1086/656802
   PubMed Web of Science ®Google Scholar
• Jing X, Ma C, Ohigashi Y, et al. Functional studies indicate amantadine binds to the pore of the influenza a virus M2 proton-selective ion channel. Proc Natl Acad Sci USA. 2008 Aug 5;105(31):10967–10972. doi: 10.1073/pnas.0804958105
   PubMed Web of Science ®Google Scholar
• Ison MG. Antiviral treatments. Clin Chest Med. 2017 Mar;38(1):139–153. doi: 10.1016/j.ccm.2016.11.008
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). High levels of adamantane resistance among influenza a (H3N2) viruses and interim guidelines for use of antiviral agents – United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2006 Jan 20;55(2):44–46.
   PubMedGoogle Scholar
• O’Hanlon R, Shaw ML. Baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol. 2019 Apr;35:14–18. doi: 10.1016/j.coviro.2019.01.006
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. [2018 Sep 6];379(10):913–923. doi: 10.1056/NEJMoa1716197
   PubMed Web of Science ®Google Scholar
• Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020 Oct;20(10):1204–1214. doi: 10.1016/S1473-3099(20)30004-9
   PubMed Web of Science ®Google Scholar
• Ringer M, Malinis M, McManus D, et al. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transpl Infect Dis. 2024 Apr;26(2):e14249. doi: 10.1111/tid.14249
   PubMed Web of Science ®Google Scholar
• Łagocka R, Dziedziejko V, Kłos P, et al. Favipiravir in therapy of viral infections. J Clin Med. 2021 Jan 13;10(2):273. doi: 10.3390/jcm10020273
   PubMed Web of Science ®Google Scholar
• Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176–186. doi: 10.1097/QCO.0000000000000532
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan G, Salam A, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically Ill patients with influenza virus infection. J Infect Dis. 2020 Apr 27;221(10):1688–1698. doi: 10.1093/infdis/jiz656
   PubMed Web of Science ®Google Scholar
• Goldhill DH, Te Velthuis AJW, Fletcher RA, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci USA. 2018 Nov 6;115(45):11613–11618. doi: 10.1073/pnas.1811345115
   PubMed Web of Science ®Google Scholar
• Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001 Feb 14;285(6):748–754. doi: 10.1001/jama.285.6.748
   PubMed Web of Science ®Google Scholar
• Duwe SC, Schmidt B, Gartner BC, et al. Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations. GMS Infect Dis. 2021;9:Doc02.
   PubMedGoogle Scholar
• Carrat F, Duval X, Tubach F, et al. Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antivir Ther. 2012;17(6):1085–1090. doi: 10.3851/IMP2128
   PubMed Web of Science ®Google Scholar
• Boikos C, Caya C, Doll MK, et al. Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. J Antimicrob Chemother. 2017 Jun 1;72(6):1556–1573. doi: 10.1093/jac/dkx013
   PubMed Web of Science ®Google Scholar
• Kumar S, Goicoechea S, Kumar S, et al. Oseltamivir analogs with potent anti-influenza virus activity. Drug Discov Today. 2020 Aug;25(8):1389–1402. doi: 10.1016/j.drudis.2020.06.004
   PubMed Web of Science ®Google Scholar
• Seo S, Englund JA, Nguyen JT, et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza a infection: safety and pharmacokinetics. Antivir Ther. 2013;18(3):377–386. doi: 10.3851/IMP2475
   PubMed Web of Science ®Google Scholar
• Kim WY, Young Suh G, Huh JW, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother. 2011 Dec;55(12):5703–5709. doi: 10.1128/AAC.05529-11
   PubMed Web of Science ®Google Scholar
• Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1201–1208. doi: 10.1007/s10096-020-03840-9
   PubMed Web of Science ®Google Scholar
• Gamino-Arroyo AE, Guerrero ML, McCarthy S, et al. Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. Clin Infect Dis. 2019 Nov 13;69(11):1903–1911. doi: 10.1093/cid/ciz100
   PubMed Web of Science ®Google Scholar
• Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014 Jul;14(7):609–618. doi: 10.1016/S1473-3099(14)70717-0
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Takashita E, Daniels RS, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020. Antiviral Res. 2022 Apr;200:105281. doi: 10.1016/j.antiviral.2022.105281
   PubMed Web of Science ®Google Scholar
• Lee N, Hurt AC. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr Opin Infect Dis. 2018 Dec;31(6):520–526. doi: 10.1097/QCO.0000000000000498
   PubMed Web of Science ®Google Scholar
• Hussain M, Galvin HD, Haw TY, et al. Drug resistance in influenza a virus: the epidemiology and management. Infect Drug Resist. 2017;10:121–134. doi: 10.2147/IDR.S105473
   PubMed Web of Science ®Google Scholar
• WHO Global Influenza Programme -Table 1. [cited 2024 Jun 11] Available from: https://cdn.who.int/media/docs/default-source/global-influenza-programme/1.-nai_human_reduced-susceptibility-marker-table-(who)_07.03.23_update.pdf?sfvrsn=eef56b17_1&download=true
   Google Scholar
• McAuley JL, Gilbertson BP, Trifkovic S, et al. Influenza virus neuraminidase structure and functions. Front Microbiol. 2019;10:39. doi: 10.3389/fmicb.2019.00039
   PubMed Web of Science ®Google Scholar
• Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983 May 5–11;303(5912):41–44. doi: 10.1038/303041a0
   PubMed Web of Science ®Google Scholar
• Burmeister WP, Ruigrok RW, Cusack S. The 2.2 a resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. Embo J. 1992 Jan;11(1):49–56. doi: 10.1002/j.1460-2075.1992.tb05026.x
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Influenza Antiviral Drug Resistance. [cited 2024 Jun 11]. Available from: https://www.cdc.gov/flu/treatment/antiviralresistance.htm
   Google Scholar
• Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17(1 Pt B):159–173. doi: 10.3851/IMP2067
   PubMed Web of Science ®Google Scholar
• Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza a H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012 Mar;12(3):240–248. doi: 10.1016/S1473-3099(11)70318-8
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Kawai N, Iwaki N, et al. In vitro neuraminidase inhibitory concentration (IC(50)) of four neuraminidase inhibitors in the Japanese 2016–17 season: Comparison with the 2010–11 to 2015–16 seasons. J Infect Chemother. 2018 Sep;24(9):707–712. doi: 10.1016/j.jiac.2018.04.009
   PubMed Web of Science ®Google Scholar
• Huang W, Cheng Y, Li X, et al. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016–2017 influenza season in Mainland China. J Infect Chemother. 2018 Sep;24(9):729–733. doi: 10.1016/j.jiac.2018.05.003
   PubMed Web of Science ®Google Scholar
• Schade D, Kotthaus J, Riebling L, et al. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza a. J Med Chem. 2014 Feb 13;57(3):759–769. doi: 10.1021/jm401492x
   PubMed Web of Science ®Google Scholar
• Zhao H, Jiang S, Ye Z, et al. Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza a neuraminidase. Eur J Med Chem. 2021 Oct 5;221:113567. doi: 10.1016/j.ejmech.2021.113567
   PubMed Web of Science ®Google Scholar
• Ai W, Zhang J, Zalloum WA, et al. Discovery of novel “Dual-site” binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors. Eur J Med Chem. 2020 Apr 1;191:112147. doi: 10.1016/j.ejmech.2020.112147
   PubMed Web of Science ®Google Scholar
• Keil JM, Rafn GR, Turan IM, et al. Sialidase inhibitors with different mechanisms. J Med Chem. 2022 Oct 27;65(20):13574–13593. doi: 10.1021/acs.jmedchem.2c01258
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin JL, Barrett S, McKenzie-Kludas C, et al. Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant. Antiviral Res. 2019 Sep;169:104542. doi: 10.1016/j.antiviral.2019.104542
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang B, Wang Y, et al. A universal dual mechanism immunotherapy for the treatment of influenza virus infections. Nat Commun. 2020 Nov 5;11(1):5597. doi: 10.1038/s41467-020-19386-5
   PubMed Web of Science ®Google Scholar
• Chan RWY, Tao KP, Ye J, et al. Inhibition of influenza virus replication by oseltamivir derivatives. Pathogens. 2022 Feb 11;11(2):237. doi: 10.3390/pathogens11020237
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Ivanenkov YA, Mitkin OD, et al. Novel oral anti-influenza drug candidate AV5080. J Antimicrob Chemother. 2014 Jul;69(7):1892–1902. doi: 10.1093/jac/dku074
   PubMed Web of Science ®Google Scholar
• Dose range study to evaluate the efficacy and safety of AV5080 in patients with influenza. [cited 2024 Jun 11]. Available from: https://www.clinicaltrials.gov/study/NCT05095545
   Google Scholar
• Jones JC, Yen HL, Adams P, et al. Influenza antivirals and their role in pandemic preparedness. Antiviral Res. 2023 Feb;210:105499. doi: 10.1016/j.antiviral.2022.105499
   PubMed Web of Science ®Google Scholar
• A study of HNC042 in healthy Chinese subjects to evaluate the safety, tolerability, and pharmacokinetics (NCT04603989). [cited 2024 Jun 11]. Available from: https://clinicaltrials.gov/study/NCT04603989
   Google Scholar
• Enkhtaivan G, Kim DH, Park GS, et al. Berberine-piperazine conjugates as potent influenza neuraminidase blocker. Int j biol macromol. 2018 Nov;119:1204–1210. doi: 10.1016/j.ijbiomac.2018.08.047
   PubMed Web of Science ®Google Scholar
• Asadi-Samani M, Altememy D, Saffari-Chaleshtor J, et al. Berberine as a new neuraminidase inhibitor drug: a systematic review [10.34172/jhp.2024.48132]. J Herbmed Pharmacol. 2024;13(1):19–27. doi: 10.34172/jhp.2024.48132
   Google Scholar
• Morimoto R, Matsubara C, Hanada A, et al. Effect of structural differences in naringenin, prenylated naringenin, and their derivatives on the anti-influenza virus activity and cellular uptake of their flavanones. Pharmaceuticals (Basel). 2022 Nov 28;15(12):1480. doi: 10.3390/ph15121480
   PubMedGoogle Scholar